No Data
Sector Update: Health Care Stocks Decline Late Afternoon
Zai Lab Announces China's NMPA Accepted NDA for KarXT
Zai Lab Limited's (NASDAQ:ZLAB) One-year Returns Climbed After Last Week's 4.4% Gain, Institutional Investors Must Be Happy
Express News | Zai Lab Says China's National Medical Products Administration Has Accepted the NDA For KarXT For Treatment Of Schizophrenia
BofA Securities Maintains Zai Lab(ZLAB.US) With Buy Rating, Maintains Target Price $29
Zai Lab's Robust Product Growth and Portfolio Expansion Drive Buy Recommendation